Építés alatt – nem éles oldal
Belépés
Toborzás még nem indultFázis nélkül

Shiwei Anshen Granules for Chronic Insomnia

A legfontosabb adatok

Ki végzi
Dongzhimen Hospital, Beijing
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Résztvevők
240 fő, tervezett
Kezdés
2026. nov. 1.
Várható befejezés
2028. okt. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Shiwei Anshen granules
  • Placebo granules
A regiszteradat frissítve
2026. október 26.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with long-lasting insomnia. They must also fit a Traditional Chinese Medicine pattern: yin deficiency with excess fire and heart-kidney imbalance. The trial tests Shiwei Anshen Granules against a placebo.

Életkor
18 to 65 years
Nem
All sexes
A betegség stádiuma
Chronic insomnia lasting ≥ 3 months, on ≥3 days per week, with at least one daytime symptom. Insomnia Severity Index (ISI) score ≥ 8 after the 2-week placebo run-in. On at least 3 of 7 diary days: falling asleep takes ≥30 minutes, awake ≥30 minutes after falling asleep, and total sleep <6.5 hours.
Korábbi kezelés
No investigational product from another drug trial within 1 month or 5 half-lives (whichever is longer) before screening.

A részvétel fő kizáró okai

  • Other sleep disorders, such as sleep apnea, restless legs syndrome or narcolepsy, unless they are gone
  • Insomnia caused by other conditions, such as chronic pain, mental illness or cancer
  • Depression (HAMD score ≥18), anxiety (HAMA score ≥14) or suicidal thoughts or behavior
  • Drug or alcohol abuse, or a positive urine drug test
  • Pregnant or breastfeeding women

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Subjects meeting the clinical diagnostic criteria for chronic insomnia disorder
  • Subjects meeting the TCM differentiation criteria for syndrome of yin deficiency with effulgent fire and disharmony between heart and kidney
  • Aged from 18 to 65 years old (both endpoints included)
  • Disease duration ≥ 3 months, with insomnia occurring ≥3 days per week. The habitual time in bed (time spent sleeping or attempting to fall asleep) ranges from 7 to 9 hours, accompanied by subjectively perceived sleep distress (complaints of dissatisfaction with nighttime sleep, manifested as difficulty falling asleep, difficulty maintaining sleep, and/or waking up earlier than expected in the morning)
  • At least one daytime symptom associated with nighttime sleep disturbance (fatigue, depressed mood or irritability, physical discomfort, cognitive impairment, anxiety, etc.)
  • Insomnia Severity Index (ISI) score ≥ 8 at the end of the placebo run-in period
  • During the consecutive 7-day sleep diary recording at the end of placebo run-in period, there are at least 3 days meeting: subjective sleep onset latency (sSOL) ≥30 minutes, subjective wake after sleep onset (sWASO) ≥30 minutes, and subjective total sleep time (sTST) <6.5 hours
  • Able to cooperate and independently complete scale assessments and recordings
  • Able to understand and voluntarily sign the informed consent form

Ki nem vehet részt

  • Previous complex sleep behaviors, such as sleep driving, sleep-related eating disorder, sleep calling and other behaviors
  • More than 10 cigarettes per day within 6 months before screening, or uncontrollable smoking before bedtime, and expected to smoke more than 10 cigarettes daily after enrollment
  • Plan to receive surgical operations during the study period
  • Allergy to the investigational product or its ingredients
  • Participation in other drug clinical trials and receiving investigational products within 1 month or 5 half-lives (whichever is longer) before screening, or concurrent participation in other research trials during this trial
  • History of sleep-related breathing disorders including chronic obstructive pulmonary disease, obstructive sleep apnea (with or without continuous positive airway pressure [CPAP] treatment), periodic limb movement disorder, myasthenia gravis, restless legs syndrome, circadian rhythm sleep-wake disorders, narcolepsy or other sleep disorders. Subjects with cured diseases mentioned above can be enrolled
  • Insomnia caused by other conditions such as chronic pain, headache, psychiatric disorders, malignant tumors, eczema, neurodermatitis, allergic rhinitis, severe dermatitis (sleep difficulty due to physical conditions or medical causes)
  • Nocturia induced or aggravated by urinary tract infection, trauma, prostate diseases and other conditions
  • Subjects with severe endocrine diseases, hematological diseases, cardiovascular and cerebrovascular diseases, gastrointestinal diseases, liver and kidney diseases, autoimmune diseases, neuropsychiatric diseases, impaired respiratory function, or other medical histories considered by researchers that may affect subject safety or interfere with study evaluation
  • History of drug abuse, or positive result in any item of urine drug screening; history of drug addiction, drug use, alcohol dependence or abuse
  • Other conditions judged by researchers making the subject inappropriate to participate in this clinical trial
  • Any lifestyle that interferes with trial progress or sleep assessment: cross-timezone travel across ≥3 time zones (Chinese mainland counts as one time zone) or shift work (alternating day and night shifts) within the recent two weeks or during the trial period
  • Daily excessive intake of tea or caffeinated beverages (defined as more than 4 cups of caffeinated drinks per day or caffeine intake>400 mg per day), or habitual consumption of caffeinated food or beverages after 18:00. If assessed as the main contributing factor for insomnia and expected to maintain such intake after enrollment
  • Depression: Hamilton Depression Scale (HAMD) score ≥18; Anxiety: Hamilton Anxiety Scale (HAMA) score ≥14; or subjects with suicidal ideation or behaviors
  • Pregnant or lactating women

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 65 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a multi-center, randomized, controlled clinical study inlcuding 240 subjects with chronic insomnia. The purpose of this study is to evaluate the efficacy and safety of Shiwei Anshen Granules (an Chinese herbal preparation) in patients with chronic insomnia. Eligible participants will be randomly assigned to receiving Shiwei Anshen Granules or the control group receiving placebo. All subjects will receive 2 weeks run-in period, followed 8 weeks of intervention and 2 weeks follow-up without treatment. The main outcome is the change in PSQI score before and after treatment. Safety indicators including routine blood, liver and kidney function and adverse events will be monitored throughout the study.

A vizsgálat 2 csoportja

  • Treatment ArmA vizsgált kezelés

    Participants take Shiwei Anshen Granules orally, twice daily for 8 weeks, combined with 2-week placebo run-in period.

    Kezelés: Shiwei Anshen granules

  • Control ArmPlacebo, összehasonlításként

    Participants take matched placebo granules orally, twice daily for 8 weeks, combined with 2-week placebo run-in period.

    Kezelés: Placebo granules

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Randomized, Double-blind, Multicenter, Placebo-controlled Clinical Trial of Shiwei Anshen Granules for Chronic Insomnia With Yin-Deficiency Fire-Hyperactivity and Heart-Kidney Disharmony Syndrome.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07895329: ki vehet részt
A regiszteradat frissítve
2026. október 26.